A Multifactorial Approach to Hepatobiliary Transporter Assessment Enables Improved Therapeutic Compound Development
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
The bile salt export pump (BSEP) is expressed at the canalicular domain of hepatocytes, where it serves as the primary route of elimination for monovalent bile acids (BAs) into the bile canaliculi. The most compelling evidence linking dysfunction in BA transport with liver injury in humans is found with carriers of mutations that render BSEP nonfunctional. Based on mounting evidence, there appears to be a strong association between drug-induced BSEP interference and liver injury in humans; however, causality has not been established. For this reason, drug-induced BSEP interference is best considered a susceptibility factor for liver injury as other host- or drug-related properties may contribute to the development of hepatotoxicity. To better understand the association between BSEP interference and liver injury in humans, over 600 marketed or withdrawn drugs were evaluated in BSEP expressing membrane vesicles. The example of a compound that failed during phase 1 human trials is also described, AMG 009. AMG 009 showed evidence of liver injury in humans that was not predicted by preclinical safety studies, and BSEP inhibition was implicated. For 109 of the drugs with some effect on in vitro BSEP function, clinical use, associations with hepatotoxicity, pharmacokinetic data, and other information were annotated. A steady state concentration (C(ss)) for each of these annotated drugs was estimated, and a ratio between this value and measured IC₅₀ potency values were calculated in an attempt to relate exposure to in vitro potencies. When factoring for exposure, 95% of the annotated compounds with a C(ss)/BSEP IC₅₀ ratio ≥ 0.1 were associated with some form of liver injury. We then investigated the relationship between clinical evidence of liver injury and effects to multidrug resistance-associated proteins (MRPs) believed to play a role in BA homeostasis. The effect of 600+ drugs on MRP2, MRP3, and MRP4 function was also evaluated in membrane vesicle assays. Drugs with a C(ss)/BSEP IC₅₀ ratio ≥ 0.1 and a C(ss)/MRP IC₅₀ ratio ≥ 0.1 had almost a 100% correlation with some evidence of liver injury in humans. These data suggest that integration of exposure data, and knowledge of an effect to not only BSEP but also one or more of the MRPs, is a useful tool for informing the potential for liver injury due to altered BA transport.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Considering that mechanisms leading to alterations in bile-acid homeostasis are believed in part to be responsible for recent prominent late-stage clinical attritions and black box warnings of novel therapeutics, including examples such as CP-724,714 (Feng et al. 2009), tolvaptan (Slizgi et al. 2016), AMG-009 (Morgan et al. 2013), and TAK-875 (Wolenski et al. 2017)”
From Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury (2017) · cites this paper as Morgan et al. 2013
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guide for the Care and Use of Laboratory Animals: Eighth Edition
(2011) · doi:10.17226/12910 · Cited by 16,199
The 1996 Guide for the Care and Use of Laboratory Animals
Clark, J. D., Gebhart, G. F., Gonder, J. C., Keeling, M. E., & Kohn, D. F. (1997) · ILAR Journal · doi:10.1093/ilar.38.1.41 · Cited by 4,417
Concordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050 · cited 4×
“…the concordance between preclinical animal safety data and human clinical outcomes for 150 development compounds and found that hepatotoxicity ( 60% concordance) and cutaneous/hypersensitivity reactions ( 40% concordance) were the 2 poorest predicted adverse events (Olson et al., 2000).”
BackgroundInfluentialBile salt transporters: molecular characterization, function, and regulation
Trauner, M., & Boyer, J. L. (2003) · Physiological Reviews · doi:10.1152/physrev.00027.2002 · Cited by 999 · cited 3×
“To mitigate potential cytotoxicity, BA homeostasis is tightly regulated by metabolic, excretion, absorption, and feedback mechanisms to limit their intracellular accumulation (Trauner and Boyer, 2003).”
BackgroundStepan, A. F., Walker, D. P., Bauman, J., Price, D. A., Baillie, T. A., Kalgutkar, A. S., & Aleo, M. D. (2011) · Chemical Research in Toxicology · doi:10.1021/tx200168d · Cited by 698
Stieger, B., Fattinger, K., Madon, J., Kullak-Ublick, G. A., & Meier, P. J. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70224-1 · Cited by 582
Fattinger, K. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.114667 · Cited by 509
The apical conjugate efflux pump ABCC2 (MRP2)
Nies, A. T., & Keppler, D. (2007) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-006-0109-y · Cited by 398
Dawson, S., Stahl, S., Paul, N., Barber, J., & Kenna, J. G. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.040758 · Cited by 343
Zollner, G., Marschall, H.-U., Wagner, M., & Trauner, M. (2006) · Molecular Pharmaceutics · doi:10.1021/mp060010s · Cited by 335
Cited by
Items 201–244 of 244
The Use of Genetically Modified Animals in Discovery Toxicology
Diaz, D., & Maher, J. M. (2016) · Wiley eBooks · doi:10.1002/9781119053248.ch19 · Cited by 3
Kenna, J. G., Persson, M., Siler, S. Q., Yu, K., Hu, C., Chen, M., Xu, J., Tong, W., Will, Y., & Aleo, M. D. (2016) · Wiley eBooks · doi:10.1002/9781119053248.ch8 · Cited by 3
Sakatis, M. Z., Norona, L. M., Karmel, J., Proctor, W. R., Sarr, F. H., Rana, P., Zane, D., Rae, J. M. C., Faber, S. C., Ravindra, K. C., et al. (2025) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5c00235 · Cited by 2
Leading-Edge Approaches for In Vitro Hepatotoxicity Evaluation
LeCluyse, E. L., Norona, L. M., Akingbasote, J. A., Howell, L. S., Woodhead, J. L., Cross, M. J., Roth, A. B., & Goldring, C. E. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64267-8 · Cited by 2
Identification of New Toxicity Mechanisms in Drug-Induced Liver Injury through Systems Pharmacology
Moya‐García, A. A., Gonzalez-Jimenez, A., Moreno, F., Stephens, C. M., Lucena, M. I., & Ranea, J. A. G. (2022) · Genes · doi:10.3390/genes13071292 · Cited by 3
“In fact, many drugs with hepatotoxicity potential, such as bosentan, pazopanib and ketoconazole, have been reported to inhibit transporter activity in vitro by binding to the bile salt export pump transporter and/or various multi-drug resistance-associated proteins, interactions assumed to be associated with DILI deve…”
BackgroundDetection of Hepatotoxicity in Clinical and Experimental Settings
Harrill, A. H. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64265-4 · Cited by 2
Mechanisms of Drug‐induced Liver Injury
Watkins, P. B., & Mosedale, M. (2017) · Wiley eBooks · doi:10.1002/9781119251316.ch28 · Cited by 4
Drug transporters in drug disposition – highlights from the year 2024
Sandoval, P., Mitra, P., Argikar, U. A., Nakakariya, M., Ramsden, D., Rotter, C. J., Tohyama, K., & Chothe, P. P. (2025) · Drug Metabolism Reviews · doi:10.1080/03602532.2025.2537399 · Cited by 1
“However, BSEP inhibition alone is not always predictive of DILI and inclusion of other transporters in DILI predictions has had some success in improving these predictions (Morgan et al. 2013).”
Shen, Y., & Liu, J. (2025) · Medicine · doi:10.1097/md.0000000000044078 · Cited by 1
“[33,34] In summary, our study found that the incidence of AT-DILI was high in patients with pulmonary tuberculosis complicated with MASLD.”
Flörl, S., Kühne, A., & Hagos, Y. (2025) · Toxics · doi:10.3390/toxics14010010 · Cited by 1
“So, the immunosuppressant cyclosporine A as well as the antibiotic rifampicin and the antiviral drugs ritonavir and amprenavir are known inhibitors of hOATP1B1 and hOATP1B3 [10,11].”
Relevance of reactive metabolites and covalent binding to drug candidate selection
Uetrecht, J. (2026) · Drug Metabolism Reviews · doi:10.1080/03602532.2026.2620682 · Cited by 2
Sjöstedt, N., Amaeze, O. U., van den Heuvel, J. J. M. W., Stage, T. B., Koenderink, J. B., Isoherranen, N., Kidron, H., & Järvinen, E. (2026) · Clinical and Translational Science · doi:10.1111/cts.70487 · Cited by 3
“Dicloxacillin was identified as a P-gp substrate in a cell assay, while it did not inhibit multidrug resistance-associated proteins (MRP) 2, 3, or 4 in membrane vesicle assays [18, 19].”
Herédi‐Szabó, K., Ito, S., Liang, X., Park, Y., Parvez, M., Sandoval, P., Shen, H., Staiger, K. M., Tetsuka, K., Warren, M. S., et al. (2026) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2026.101528 · Cited by 2
Takemura, A., Naito, S., Higuchi, Y., Uehara, S., Yoneda, N., Suemizu, H., & Ito, K. (2026) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2026.101530 · Cited by 1
ComTarget: Small-Molecule Target Prediction with Combinatorial Modeling
Li, Y., Shi, Q., Lu, X., Yang, D., Yeerken, D., Jin, H., & Sun, Q. (2026) · Pharmaceuticals · doi:10.3390/ph19050715 · Cited by 1
Bile Salt Export Pump: Drug-Induced Liver Injury and Assessment Approaches
Deng, R. (2018) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-7677-5_15 · Cited by 2
Study on the Characteristics of Small-Molecule Kinase Inhibitors-Related Drug-Induced Liver Injury
Dong, H., You, J., Zhao, Y., Zheng, D., Zhong, Y., Li, G., Weng, Z., Luo, H., & Jiang, S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.838397 · Cited by 2
Nautiyal, M., Bauch, C., Walker, P., Watkins, P. B., & Mosedale, M. (2020) · Applied In Vitro Toxicology · doi:10.1089/aivt.2020.0005 · Cited by 1
Mechanism‐Based Experimental Models for the Evaluation of BSEP Inhibition and DILI
Murphy, W. A., Saran, C., Honkakoski, P., & Brouwer, K. L. R. (2021) · Wiley eBooks · doi:10.1002/9781119171003.ch9 · Cited by 1
Umemori, Y., D, K. H. M., Yoshimura, S., Kageyama, M., & Iijima, T. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.12.580017 · Cited by 1
Stieger, B., & Kullak-Ublick, G. A. (2015) · Methods and principles in medicinal chemistry · doi:10.1002/9783527673643.ch08
Mechanistic Modeling of Drug‐Induced Liver Injury (DILI)
Yang, K., Woodhead, J. L., Shoda, L. K. M., Yang, Y., Watkins, P. B., Brouwer, K. L. R., Howell, B. A., & Siler, S. Q. (2015) · Methods and principles in medicinal chemistry · doi:10.1002/9783527673643.ch09
Köck, K., Ferslew, B. C., Netterberg, I., Yang, K., Urban, T. J., Swaan, P. W., Stewart, P. W., & Brouwer, K. L. R. (2014)
Two Liver Transporters, ABCB11 and ABCC6; Novel Therapeutic Approaches in the Related Disorders
Váradi, A., & Homolya, L. (2015) · Springer eBooks · doi:10.1007/978-3-319-23476-2_15
Small‐Molecule Safety Lead Optimization
Dambach, D. M. (2016) · Wiley eBooks · doi:10.1002/9781119053248.ch2
Mechanisms of drug-induced liver injury: the role of hepatic transport proteins
Yang, K. (2014) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/tzn9-dw77
Research advances in pathogenesis and diagnostic markers of drug-induced liver injury
Yang, C., & Yao, D.-M. (2021) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v29.i13.726
Jungsuwadee, P., & Vore, M. E. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.99186-4
How to reduce risk of drug induced liver toxicity from the beginning
Gan, J., He, K., & Humphreys, W. G. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-817134-9.00010-6 · Cited by 1
Yoon, J., Song, H., Park, J. S., Kim, J. H., Jun, Y., Gim, S.-A., Hong, C., An, K. M., Park, J.-T., Lee, J. W., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117674 · Cited by 1
Uzu, M., & Takezawa, T. (2025) · The Journal of Toxicological Sciences · doi:10.2131/jts.50.135
Idiosyncratic Drug-Induced Liver Injury: Mechanisms and Susceptibility Factors
Stephens, C. M., Lucena, M. I., & Andrade, R. J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.00276-x
Regulation of Hepatobiliary Transporters During Liver Injury
Aleksunes, L. M., Ghanem, C. I., & Manautou, J. E. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.00268-0
Sjöstedt, N., Amaeze, O. U., van den Heuvel, J. J. M. W., Stage, T. B., Koenderink, J. B., Isoherranen, N., Kidron, H., & Järvinen, E. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.21.683780
Advances in the Pathogenesis of Drug-Induced Liver Injury
焦, 军. (2022) · Pharmacy Information · doi:10.12677/pi.2022.113022
“胆汁酸是有毒物质,遗传缺陷导致胆盐输出泵(bile salt export pump, BSEP)活性缺失,引起肝衰竭[23] [24]。缺乏 BSEP 活性的患者最常见的临床表现是碱性磷酸酶升高的胆汁淤积性肝损伤。但与大多数胆汁 淤积性肝损伤不同的是,血清 γ谷氨酰转肽酶通常是正常的。大多数被认为通过这一机制引起的 DILI 是”
Jackson, J. P., & Brouwer, K. R. (2025) · Applied In Vitro Toxicology · doi:10.1177/23321539251399331
Schieferdecker, S., Woelflingseder, L., & Lott, J. (2026) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6c00364
Stergiopoulos, C., & Valko, K. L. (2026) · ADMET & DMPK · doi:10.5599/admet.3303
“A dataset comprising 62 structurally diverse compounds with reported BSEP inhibition data (IC₅₀ values) was compiled from published in vitro vesicle-based transporter assays and curated datasets, primarily from Morgan et al. [6], Pedersen et al. [7], Montanari et al. [8], and Dawson et al. [18].”
Drug transporters in drug disposition – highlights from the year 2025
Sandoval, P., Mitra, P., Nakakariya, M., Ramsden, D., Rotter, C. J., Ding, N., & Chothe, P. P. (2026) · Drug Metabolism Reviews · doi:10.1080/03602532.2026.2690529
Liu, B., Liu, Y., Yang, H., Li, Y., Yin, S., Wang, J., Cheng, Z., Zhao, X., Zhang, X., Li, S., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1911283
“BSEP inhibition data were acquired from three key literature sources: Warner et al. (2012), Morgan et al. (2013) and Sutherland et al. (2023), and their experimental measurements were consolidated into a unified dataset.”
New approach methodologies for in vitro detection of chemical-induced cholestatic liver injury
Maerten, A., Avîrvarei, A.-C., & Vinken, M. (2026) · Archives of Toxicology · doi:10.1007/s00204-026-04541-6
Norona, L. M., Melnikov, F., Kiyota, T., Lawson, C., Khojasteh, C., Liu, J., Johnson, K. M., Pourmohamad, T., Anger, L. T., Proctor, W. R., et al. (2026) · Toxicological Sciences · doi:10.1093/toxsci/kfag124
“Despite these limitations, convergence across multiple hazards can enrich for drugs associated with severe hepatotoxicity (Aleo et al. 2014) and partition compound sets into regions largely comprising known hepatotoxicants (Morgan et al. 2013; Shah et al. 2015).”
BindingDB Entry 50014961: Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA
BindingDB (2023) · UC San Diego · doi:10.7270/q2pz5dp9
Metadata
- Authors
- Morgan, R. E., van Staden, C. J., Chen, Y., Kalyanaraman, N., Kalanzi, J., Dunn, R. T., Afshari, C. A., & Hamadeh, H. K.
- Affiliations
- Amgen (United States) (US)
- Venue
- Toxicological Sciences
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-08-16
- Volume
- 136
- Issue
- 1
- Pages
- 216-241
- ISSN
- 1096-0929 (ISSN-L)
- 1096-6080
- OpenAlex
- W2152548885
- Cited by
- 243
- References
- 41
- Citations by year
- 2026: 12 · 2025: 19 · 2024: 14 · 2023: 14 · 2022: 15 · 2021: 13 · 2020: 12 · 2019: 24 · 2018: 20 · 2017: 33 · 2016: 30 · 2015: 24 · 2014: 11 · 2013: 2
- FWCI
- 11.95
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Toxicological Sciences (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- bile salt export pump, drug-induced liver injury, hepatotoxicity, bile acid transport, multidrug resistance-associated protein, MRP2, MRP3, MRP4, steady-state concentration, hepatobiliary transporters, drug safety assessment
- MeSH terms
- ATP Binding Cassette Transporter, Subfamily B, Member 11, Animals, Biological Transport, Humans, Liver, Male, Pharmacokinetics, Recombinant Proteins, Risk Factors, Cluster Analysis, Rats, Sprague-Dawley, ATP Binding Cassette Transporter, Subfamily B, ATP-Binding Cassette Transporters, Risk Assessment, Toxicity Tests, ATP-Binding Cassette, Sub-Family C Proteins, Rats, Chemical and Drug Induced Liver Injury, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.